drugset / Trial / NCT03602339

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

NCT03602339

Phase 4 Completed 157 enrolled Bayer
Non-randomizedCrossoverOpen-labelDiagnostic

Summary

The study was conducted to gain knowledge about a new dose of a diagnostic drug that is used for contrast-enhanced Magnetic Resonance Imaging (MRI) of the human central nervous system (CNS). MRI can visualize the anatomy of the body and is used to detect medical conditions. Diagnostic drugs like gadobutrol and gadoterate contain an element called gadolinium that is applied to improve the analysability of MRI-images. The purpose of this study was to examine if contrast-enhanced MRI using a reduced dose of the gadolinium-based contrast agent gadobutrol delivers images of similar quality to those obtained when a full dose of the gadolinium-based contrast agent gadoterate was used.

Timeline

Start
2018-11-14
Primary completion
2020-03-13
Completion
2020-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadobutrol Diagnostic / imaging agent 0.075 mmol Intravenous
Subject Gadoterate Diagnostic / imaging agent 0.1 mmol Intravenous

Indications

No indication recorded.